Bonify Signs Binding Supply Agreement to Enter the International Medical Cannabis Marketplace

< Back to all articles

WINNIPEG, Manitoba, Sept. 12, 2018 (GLOBE NEWSWIRE) — Bonify, Manitoba’s largest licensed producer of quality-assured medical cannabis, is pleased to announce it has signed a binding Supply Agreement with ADREXpharma, a leading Germany-based distributor of medical cannabis products.

Under the terms of the agreement, Bonify will provide ADREXpharma with monthly exports of its premium cannabis solutions to meet the needs of Germany’s medical cannabis patients. Deliveries to Germany will begin immediately following Bonify’s anticipated receipt of European Medical Agency Good Manufacturing Practices (“GMP”) certification and export permit from Health Canada.

Germany is fast becoming the largest federally regulated medical cannabis market in the world, with a population of over 82 million, approximately 89% of whom are covered by the public health insurance program and the remainder covered by private insurance plans.  Domestic demand for medical cannabis product in Germany is expected to far outstrip domestic supply for years to come.  Additionally, the German market is well positioned as a potential gateway to supplying other European markets.

Dalbir Bains, Bonify’s President and CEO states, “We are thrilled to be working with ADREXpharma to extend our reach across the globe and add to the number of patients we are helping live better lives.”  Reinforcing the sentiment, Mario Eimuth, CEO of ADREXpharma states, “Bonify, who shares our patient-centric focus, is an ideal partner for us to work with to serve German patients in need.”

About Bonify

Bonify is a Canadian-owned leading provider of quality medical Cannabis. By maximizing research findings and strictly adhering to best in class practices, quality standards and procedures, Bonify produces Cannabis solutions to help individuals get the most out of life each and every day.

To learn more, please visit

About ADREXpharma GmbH

ADREXpharma® GmbH is an independent German pharmaceutical company with a strong focus on Controlled Drugs and Medical Cannabis distribution. Committed to quality, authenticity and innovation, as well as to contributing to the growing body of evidence-based research regarding the benefits and efficacy of cannabis to validate new therapy options for patients, ADREXpharma’s aim is to provide the best possible treatment for medical cannabis patients – today and always.

Forward Looking Statements:

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

< Previous PostHow To Purchase Medical Cannabis Next Post >Bonify Signs Binding Supply Agreement for the Province of Manitoba